ALS drug development

Business news, market intelligence, and global industry analysis.

The Latest

Will Iran strikes on Dubai delay Wynn Al Marjan Island and what does it mean for WYNN investors?

Blackstone (NYSE: BX) to acquire majority stake in Advanced Cooling Technologies as AI data centre heat surge reshapes thermal management market

Representative image of enterprise data center infrastructure and networking hardware illustrating Hewlett Packard Enterprise’s fiscal 2026 growth momentum, as strong networking revenue following the Juniper Networks acquisition drives higher earnings, improved free cash flow, and renewed investor focus on HPE’s evolving AI and infrastructure strategy.

Hewlett Packard Enterprise (NYSE: HPE) raises FY2026 guidance after Q1 beat fuelled by Juniper integration and AI networking demand

Representative image: Oracle (NYSE: ORCL) stock jumps 13% on record cloud earnings and multicloud momentum

Oracle (NYSE: ORCL) rallies 10% after earnings as $553bn RPO signals AI infrastructure dominance

Neurizon Therapeutics (ASX: NUZ) just crossed the threshold every ALS biotech dreams about. Now the hard part starts.

Neurizon Therapeutics (ASX: NUZ) doses first ALS patient in the HEALEY Platform Trial. What the Phase 2/3 design means for investors and the sector. Read more.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

February 27, 2026